NEKTAR THERAPEUTICS (NKTR) Stock Price & Overview
NASDAQ:NKTR • US6402683063
Current stock price
The current stock price of NKTR is 75.71 USD. Today NKTR is up by 5.23%. In the past month the price increased by 6.47%. In the past year, price increased by 814.54%.
NKTR Key Statistics
- Market Cap
- 2.172B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -10.20
- Dividend Yield
- N/A
NKTR Stock Performance
NKTR Stock Chart
NKTR Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to NKTR. When comparing the yearly performance of all stocks, NKTR is one of the better performing stocks in the market, outperforming 99.55% of all stocks.
NKTR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NKTR. Both the profitability and financial health of NKTR have multiple concerns.
NKTR Earnings
On March 12, 2026 NKTR reported an EPS of -1.78 and a revenue of 21.81M. The company beat EPS expectations (29.47% surprise) and beat revenue expectations (105.49% surprise).
NKTR Forecast & Estimates
14 analysts have analysed NKTR and the average price target is 139.16 USD. This implies a price increase of 83.8% is expected in the next year compared to the current price of 75.71.
For the next year, analysts expect an EPS growth of 3.78% and a revenue growth -6.31% for NKTR
NKTR Groups
Sector & Classification
NKTR Financial Highlights
Over the last trailing twelve months NKTR reported a non-GAAP Earnings per Share(EPS) of -10.2. The EPS increased by 12.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.51% | ||
| ROE | -182.65% | ||
| Debt/Equity | 0.7 |
NKTR Ownership
NKTR Latest News, Press Relases and Analysis
NKTR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 27.31 | 900.456B | ||
| JNJ | JOHNSON & JOHNSON | 20.96 | 587.99B | ||
| MRK | MERCK & CO. INC. | 23.35 | 298.764B | ||
| PFE | PFIZER INC | 9.56 | 162.403B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.75 | 125.711B | ||
| ZTS | ZOETIS INC | 16.57 | 49.512B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 27.972B | ||
| VTRS | VIATRIS INC | 5.43 | 15.693B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.98 | 11.495B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.787B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.274B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.606B | ||
| CORT | CORCEPT THERAPEUTICS INC | 50.81 | 4.465B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NKTR
Company Profile
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is headquartered in San Francisco, California and currently employs 63 full-time employees. The company is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Company Info
IPO: 1994-05-03
NEKTAR THERAPEUTICS
455 Mission Bay Boulevard South
San Francisco CALIFORNIA 94158 US
CEO: Howard W. Robin
Employees: 63
Phone: 13026587581
NEKTAR THERAPEUTICS / NKTR FAQ
What does NKTR do?
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is headquartered in San Francisco, California and currently employs 63 full-time employees. The company is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
What is the current price of NKTR stock?
The current stock price of NKTR is 75.71 USD. The price increased by 5.23% in the last trading session.
Does NEKTAR THERAPEUTICS pay dividends?
NKTR does not pay a dividend.
How is the ChartMill rating for NEKTAR THERAPEUTICS?
NKTR has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy NKTR stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NKTR.
Can you provide the number of employees for NEKTAR THERAPEUTICS?
NEKTAR THERAPEUTICS (NKTR) currently has 63 employees.
What is the outstanding short interest for NEKTAR THERAPEUTICS?
The outstanding short interest for NEKTAR THERAPEUTICS (NKTR) is 13.53% of its float.